Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, IDEXX LABORATORIES INC /DE reported revenue of $4.30B, up 10.4% year over year. Operating margin was 31.6% and net margin 24.6%, on a free-cash-flow margin of 24.6% with capital expenditure at 2.9% of revenue. Every figure is computed directly from IDXX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4.30B | 31.6% | 24.6% |
| FY2024 | $3.90B | 29.0% | 22.8% |
| FY2023 | $3.66B | 30.0% | 23.1% |
| FY2022 | $3.37B | 26.7% | 20.2% |
| FY2021 | $3.22B | 29.0% | 23.2% |
How does IDXX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.